Short answer · Medically reviewed summary · Last updated: 2026-04-07
Pheochromocytoma was first described in the medical literature in the late 19th century, with the term itself coined by Ludwig Pick in 1912 to describe the tumor's characteristic staining properties. Over the past century, understanding has shifted from viewing Pheochromocytoma as a fatal, often undiagnosed "great mimic" to a manageable condition driven by complex genetic pathways and advanced biochemical testing. When and how was Pheochromocytoma first described? The history of Pheochromocytoma begins in 1886 when Felix Fränkel described a young woman with paroxysmal palpitations, anxiety, and hypertension, who died suddenly.
3 people with Pheochromocytoma have shared their first-person experience on this question at DiseaseMaps.
Pheochromocytoma was first described in the medical literature in the late 19th century, with the term itself coined by Ludwig Pick in 1912 to describe the tumor's characteristic staining properties. Over the past century, understanding has shifted from viewing Pheochromocytoma as a fatal, often undiagnosed "great mimic" to a manageable condition driven by complex genetic pathways and advanced biochemical testing.
The history of Pheochromocytoma begins in 1886 when Felix Fränkel described a young woman with paroxysmal palpitations, anxiety, and hypertension, who died suddenly. An autopsy revealed bilateral adrenal tumors. The name Pheochromocytoma—derived from the Greek phaios (dusky), chroma (color), and kytos (cell)—was introduced by Ludwig Pick in 1912 because of the tumor cells' ability to stain dark brown when exposed to chromium salts. For many years, these tumors were often discovered only during autopsies, as clinical recognition remained poor.
Early clinicians struggled to link the tumor to the systemic "storm" of symptoms patients experienced. The breakthrough came in the 1940s and 1950s when researchers identified that Pheochromocytoma cells secrete catecholamines (epinephrine and norepinephrine). This discovery transformed the condition from a mysterious endocrine curiosity into a biochemical disease that could be measured in urine and blood. With 165 members currently sharing their experiences on DiseaseMaps.org, we have seen firsthand how the patient community has moved from isolated confusion to an era of informed, personalized care.
The management of Pheochromocytoma has undergone a revolution, shifting from high-risk exploratory surgery to precision medicine. Key historical milestones include:
Previously, Pheochromocytoma was often misdiagnosed as simple anxiety or essential hypertension. Today, we understand that these tumors are frequently part of inherited syndromes, such as Multiple Endocrine Neoplasia (MEN) type 2 or Von Hippel-Lindau (VHL) disease. This genetic insight has shifted the focus from merely "removing the tumor" to comprehensive family screening and lifelong surveillance, ensuring that carriers of genetic mutations receive early intervention before tumors become symptomatic or malignant.
Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.